Federated Hermes Inc. Increases Holdings in Inogen, Inc. (NASDAQ:INGN)

Federated Hermes Inc. raised its position in Inogen, Inc. (NASDAQ:INGN - Free Report) by 347.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 265,485 shares of the medical technology company's stock after acquiring an additional 206,125 shares during the quarter. Federated Hermes Inc. owned approximately 1.14% of Inogen worth $1,458,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of INGN. SG Americas Securities LLC raised its stake in Inogen by 27.8% during the 4th quarter. SG Americas Securities LLC now owns 12,782 shares of the medical technology company's stock valued at $70,000 after purchasing an additional 2,782 shares during the period. Strs Ohio raised its stake in Inogen by 9.0% during the 4th quarter. Strs Ohio now owns 41,300 shares of the medical technology company's stock valued at $226,000 after purchasing an additional 3,400 shares during the period. Paradigm Capital Management Inc. NY bought a new stake in Inogen during the 3rd quarter valued at approximately $52,000. Glenmede Trust Co. NA raised its stake in Inogen by 39.8% during the 3rd quarter. Glenmede Trust Co. NA now owns 39,670 shares of the medical technology company's stock valued at $207,000 after purchasing an additional 11,285 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in Inogen during the 3rd quarter valued at approximately $79,000. Institutional investors own 89.94% of the company's stock.

Inogen Price Performance

INGN traded down $0.22 during trading hours on Tuesday, reaching $6.80. 178,421 shares of the company's stock traded hands, compared to its average volume of 541,417. The firm has a 50-day moving average price of $7.34 and a 200 day moving average price of $6.40. Inogen, Inc. has a 52-week low of $4.13 and a 52-week high of $14.10.

Inogen (NASDAQ:INGN - Get Free Report) last announced its earnings results on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.49). Inogen had a negative net margin of 32.46% and a negative return on equity of 38.98%. The business had revenue of $75.90 million for the quarter, compared to analyst estimates of $78.09 million. As a group, sell-side analysts anticipate that Inogen, Inc. will post -2.56 EPS for the current year.

Analyst Ratings Changes

INGN has been the topic of several recent analyst reports. William Blair raised Inogen from a "market perform" rating to an "outperform" rating in a research note on Thursday, February 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research note on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $7.50.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.